,96 Remarkably, CEP-1347, a therapeutic agent for chronic liver disease and liver fibrosis, targets RPS5 to inhibit the expression of p70S6K and the activation of hepatic stellate cells, effectively blocking the progression of liver fibrosis.97 Here, RPS5 is linked to Hepatic fibrosis.